CMMB vs. TENX, CYCN, BNOX, OBSV, ASLN, HEPA, ADXN, CANF, TRVN, and VCNX
Should you be buying Chemomab Therapeutics stock or one of its competitors? The main competitors of Chemomab Therapeutics include Tenax Therapeutics (TENX), Cyclerion Therapeutics (CYCN), Bionomics (BNOX), ObsEva (OBSV), ASLAN Pharmaceuticals (ASLN), Hepion Pharmaceuticals (HEPA), Addex Therapeutics (ADXN), Can-Fite BioPharma (CANF), Trevena (TRVN), and Vaccinex (VCNX). These companies are all part of the "pharmaceutical preparations" industry.
Tenax Therapeutics (NASDAQ:TENX) and Chemomab Therapeutics (NASDAQ:CMMB) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, institutional ownership, community ranking, profitability, dividends, valuation, analyst recommendations, earnings and media sentiment.
Tenax Therapeutics presently has a consensus price target of $480.00, suggesting a potential upside of 13,233.33%. Chemomab Therapeutics has a consensus price target of $6.50, suggesting a potential upside of 796.55%. Given Chemomab Therapeutics' higher possible upside, research analysts plainly believe Tenax Therapeutics is more favorable than Chemomab Therapeutics.
In the previous week, Chemomab Therapeutics had 4 more articles in the media than Tenax Therapeutics. MarketBeat recorded 4 mentions for Chemomab Therapeutics and 0 mentions for Tenax Therapeutics. Tenax Therapeutics' average media sentiment score of 0.50 beat Chemomab Therapeutics' score of 0.00 indicating that Chemomab Therapeutics is being referred to more favorably in the news media.
Chemomab Therapeutics' return on equity of -65.79% beat Tenax Therapeutics' return on equity.
Tenax Therapeutics has a beta of 2.25, indicating that its share price is 125% more volatile than the S&P 500. Comparatively, Chemomab Therapeutics has a beta of 0.39, indicating that its share price is 61% less volatile than the S&P 500.
Tenax Therapeutics received 125 more outperform votes than Chemomab Therapeutics when rated by MarketBeat users. However, 60.00% of users gave Chemomab Therapeutics an outperform vote while only 58.58% of users gave Tenax Therapeutics an outperform vote.
1.7% of Tenax Therapeutics shares are owned by institutional investors. Comparatively, 46.1% of Chemomab Therapeutics shares are owned by institutional investors. 1.9% of Tenax Therapeutics shares are owned by company insiders. Comparatively, 11.9% of Chemomab Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
Summary
Tenax Therapeutics and Chemomab Therapeutics tied by winning 6 of the 12 factors compared between the two stocks.
Get Chemomab Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for CMMB and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CMMB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Chemomab Therapeutics Competitors List
Related Companies and Tools
